Biogenera

Name

Biogenera

Legal name

BIOGENERA SpA

Website

https://biogenera.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAAAAH

Therapeutic Peptides & Protein/Peptide Biologics

Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

SECONDARYHLAAAIAD

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAACAF

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)

Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

• Anti-gene oligonucleotide drugs
• Gene silencing therapeutics
• PNA drug development
• Pediatric oncology drugs
• Precision medicine biotechnology

Headquarters

HQ city

Bologna

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical drug development and commercialization: Pre-revenue biotech company developing personalized DNA drugs. Revenue expected from pharmaceutical sales upon regulatory approval of drug candidates in pipeline.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Biogenera is an Italian biotechnology company that develops proprietary anti-gene peptide nucleic acid (Ag-PNA) oligonucleotide drugs designed to silence disease-causing genes at the DNA level. Its lead programs target the MYCN oncogene for pediatric cancers such as neuroblastoma, medulloblastoma, and rhabdomyosarcoma, using the MyGenera™ discovery and development platform to identify and advance Ag-PNA drug candidates through preclinical and clinical stages.

Product overview

Biogenera develops a new generation of anti-gene PNA (Peptide Nucleic Acid) oligonucleotide drugs through its proprietary MyGenera™ platform. The company operates as a pharmaceutical biotechnology company specializing in personalized DNA biotechnological drugs for treating serious diseases. The pipeline consists of three main candidates: BGA002 (pediatric cancers targeting MYCN gene, in Phase I preparation), BGA003 (adult aggressive tumors targeting MYC gene, in preclinical stage), and BGA00X (rare genetic diseases, in discovery phase).

Differentiator

Problem solved

Functional benefit

Brands

• MyGenera™: Proprietary patented technology platform that rapidly identifies anti-gene PNA (Ag-PNA) oligonucleotides capable of selectively targeting altered disease genes.

Products and services

• MyGenera™ Platform Proprietary discovery and development platform that uses anti-gene peptide nucleic acid (Ag-PNA) oligonucleotide chemistry to identify and design gene-silencing drug candidates that bind directly to double-stranded DNA to block transcription of disease-causing genes.
• BGA002 Lead Ag-PNA oligonucleotide drug candidate designed to silence the MYCN oncogene for the treatment of pediatric solid tumors including neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
• BGA003 Pipeline Ag-PNA oligonucleotide drug candidate developed using Biogenera's anti-gene PNA technology, part of the company's broader pipeline of gene-silencing therapeutics.
• BGA00X Additional early-stage Ag-PNA oligonucleotide drug candidate in Biogenera's pipeline, developed using the MyGenera™ platform.

Quantifiable outcome

• Orphan Drug Designation obtained from both EMA and FDA
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• University of BolognacoreStrategic or Co-development PartnerPrimary academic partnership for scientific research and development; co-founder scientific partner Roberto Tonelli associated with the university
• University of ChicagocoreStrategic or Co-development PartnerJoint preclinical studies on MYCN and neuroblastoma; focuses on efficacy of BGA002 in advanced neuroblastoma models
• University of PadovacoreStrategic or Co-development PartnerClinical development partnership with Prof. Alessandra Biffi leading the Phase I clinical trial
• European Medicines Agency (EMA)coreOthersRegulatory agency for European clinical trial authorization and orphan drug designation
• U.S. Food and Drug Administration (FDA)coreOthersUS regulatory agency providing orphan drug designation for BGA002
• Computershare ItaliaminorOthersCorporate trust and stock transfer services for corporate structure management

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Dyne Therapeutics: Clinical-stage company developing oligonucleotide-based therapeutics for serious muscle diseases, with a focus on rare genetic disorders. Comparable as a nucleic acid therapeutics developer targeting rare diseases with platform technology.
• Y-mAbs Therapeutics: Commercial-stage biopharmaceutical company focused on pediatric oncology, with approved and pipeline therapies for neuroblastoma and other pediatric cancers. Comparable in target indication (BGA002 also targets neuroblastoma) and pediatric oncology focus.
• Stoke Therapeutics: Clinical-stage antisense oligonucleotide company developing treatments for severe genetic diseases, including pediatric indications. Comparable as a nucleic-acid therapeutics developer with a similar modality-overlapping approach and rare disease focus.
• ProQR Therapeutics: RNA-focused therapeutics company developing Axiomer RNA editing technology and antisense oligonucleotides for genetic disorders. Comparable as a nucleic-acid platform company targeting rare genetic diseases with proprietary chemistry and pipeline leverage.
• Wave Life Sciences: Stereopure oligonucleotide therapeutics company targeting rare genetic diseases and neurological disorders. Comparable as a platform-driven nucleic acid therapeutics company with multiple pipeline candidates and proprietary chemistry, similar to Biogenera's MyGenera platform model.

Broad incumbents

• Sarepta Therapeutics: Established RNA-based therapeutics company with multiple approved drugs for Duchenne muscular dystrophy and other rare diseases. Comparable as a nucleic acid therapeutics developer with orphan drug designations and premium rare disease pricing, though larger and more commercially mature.
• Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics leader with multiple approved drugs. Directly comparable to Biogenera as a nucleic acid-based drug developer targeting disease genes, though Biogenera's PNA anti-gene chemistry is distinct from Ionis's modified RNA ASO platform.
• Alnylam Pharmaceuticals: Leading RNAi therapeutics company with multiple approved siRNA drugs. Comparable as a nucleic acid therapeutics platform company developing gene-silencing drugs, though Biogenera's PNA anti-gene approach targets DNA directly versus Alnylam's RNA interference at the mRNA level.

Regional players

• Philogen: Italian-Swiss biotechnology company developing antibody-based therapeutics for cancer and inflammatory diseases, listed on the Italian stock exchange. Comparable as a European clinical-stage biotech with oncology focus, though Philogen uses antibody technology rather than PNA oligonucleotides.
• Genenta Science: Italian clinical-stage biotech developing gene therapies for solid tumors, listed on Nasdaq. Comparable as a small Italian biotech pursuing innovative oncology therapeutics with a clear path to US capital markets, similar to Biogenera's Euronext IPO trajectory.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/BIOGENERA

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biogenera